Discover 1,431 paid clinical trials in St. Petersburg, Florida. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,431
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
for
Heart Failure - NYHA II - IV
Location: Tampa FL, Sarasota FL, Mobile AL, Atlanta GA,
Location: Tampa FL, Weston FL, Coral Gables FL, Atlanta GA,
Sponsor: ECRI bv
Sex: All
Age: 18+
Code: NCT06625801
Recruiting
A Prospective, Single-Center Investigation of the da Vinci SP® Surgical System in Hepatopancreaticobiliary and Foregut Operations for Benign and Malignant Disease
for
Hepatopancreaticobiliary and Foregut Operations
Location: Tampa FL
Sponsor: AdventHealth
Sex: All
Age: 18 - 70+
Code: NCT06562179
Recruiting
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
for
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC),
Location: Sarasota FL, Nashville TN, Columbus OH, San Antonio TX,
Sponsor: Olema Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT06784193
Phase 1, Recruiting
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
for
Heart Failure, Acute Heart Failure
Location: Bradenton FL, Brooksville FL, Fort Myers FL, Tamarac FL,
Sponsor: Colorado Prevention Center
Sex: All
Age: 18+
Code: NCT06008197
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Child and Adolescent Registry for Participants With Narcolepsy
for
Narcolepsy
Location: Tampa FL, Norfolk VA, Little Rock AR, Houston TX,
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
for
Pulmonary Arterial Hypertension
Location: Tampa FL, Providence RI, Boston MA
Sponsor: 35Pharma Inc., a GSK company
Sex: All
Age: 18+
Code: NCT07143448
Phase 1, Phase 2, Recruiting
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod